Real-World Utilization Pattern and Outcomes of Letermovir in Adult Cytomegalovirus-Seropositive Allogeneic Hematopoietic Cell Transplant Recipients: An International Retrospective Study From the Infec
8 hours ago
- #CMV prophylaxis
- #allogeneic HCT
- #letermovir
- Study analyzed letermovir for CMV primary prophylaxis in adult CMV-seropositive allo-HCT recipients.
- Retrospective study included 481 adults from 2018-2020 with a median follow-up of 33.8 months.
- Median letermovir start time was 3 days post-transplant, with median prophylaxis duration of 100 days.
- Cumulative incidence of csCMVi was 2.7% at 3 months, 13.1% at 6 months, and 17.1% at 12 months.
- Factors contributing to csCMVi: reduced-intensity conditioning, peripheral blood cell source, D-/R+ serostatus, alemtuzumab use.
- No difference in csCMVi incidence in first 100 days between early (≤5 days) vs. late (>5 days) letermovir start.
- Adverse factors for overall survival: age, male sex, disease status > CR1, PB stem cell source, acute leukemia diagnosis, CMV high-risk.
- Real-world use of letermovir showed low csCMVi incidence compared to previous data.